Pluristem Therapeutics Profit Margin

The latest profit margin for PSTI is -870.11% as of March 2026. That compares with -3010.28% in the prior-year period — up 71.1% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Pluristem Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PSTI's profit margin moved from -3010.28% to -870.11% — a 71.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pluristem Therapeutics's valuation or profitability profile.

Against Healthcare companies, PSTI currently prints -870.11% for profit margin, while the sector average sits near 14.41%. That is roughly 6136.2% below the sector mean. Large gaps often invite a closer look at Pluristem Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Pluristem Therapeutics converts resources into returns. At -870.11%, PSTI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3010.28% in the prior-year period — up 71.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PSTI's profit margin (-870.11%), review year-over-year change from -3010.28%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.